Avicanna Inc. (0NN.F)
| Previous Close | 0.2800 |
| Open | 0.2480 |
| Bid | 0.2560 x N/A |
| Ask | 0.2880 x N/A |
| Day's Range | 0.2480 - 0.2480 |
| 52 Week Range | 0.1610 - 0.3760 |
| Volume | |
| Avg. Volume | 37 |
| Market Cap | 26.971M |
| Beta (5Y Monthly) | 1.53 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0700 |
| Earnings Date | May 13, 2024 - May 17, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswireAvicanna Announces Closing of Non-brokered Private Placement
TORONTO, April 18, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce that it has closed a non-brokered private placement offering of 5,313,959 units of the Company (the “Units”) at a price of $0.40 per Unit for aggregate gross proceeds of approximately of $2,125,000. “We are very
GlobeNewswireAvicanna Announces Completion of Topical Gel Observational Real-World Evidence Study
The study results revealed improvements in symptoms and quality of life in patients with musculoskeletal pain and inflammationTORONTO, April 10, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce the completion of its observational real-world evidence (“RWE”) study using RHO Phyto br
Simply Wall St.Avicanna Full Year 2023 Earnings: CA$0.10 loss per share (vs CA$0.25 loss in FY 2022)
Avicanna ( TSE:AVCN ) Full Year 2023 Results Key Financial Results Revenue: CA$16.8m (up 315% from FY 2022). Net loss...
